RMD Open 2022 doi:10.1136/rmdopen-2022-002253
Navarro-Compán et al, determined the effectiveness of tofacitinib in patients with active ankylosing spondylitis in a Phase III, randomised, double-blind, placebo-controlled trial.
This study provided evidence of association of tofacitinib treatment with clinically meaningful benefits, across a wide range of patient-reported outcomes including pain, fatigue, health-related quality of life and work productivity. Improvements in pain and fatigue were reported as early as Week 2. Improvements in all areas were observed at Week 16 and were sustained to Week 48. Moreover, the percentage of patients with improvements greater than minimum clinically important difference in patient reported outcome was also higher in the tofacitinib treated group.